Scientists Crack Code Behind Drug Resistance in Advanced Breast Cancer

Scientists have uncovered a key mechanism behind drug resistance in advanced breast cancer. The study focuses on estrogen receptor alpha (ERα), a critical factor in around 70% of global breast cancer cases. Their findings explain why some patients stop responding to newer treatments. The research highlights luminal lineage loss as a major cause of resistance. When cancer cells lose their luminal identity, they shift to a stem-like state with reduced drug sensitivity. This change also alters chromatin structure and epigenetic markers, weakening the effect of ERα-targeting drugs.

Current treatments for ER+ HER2- breast cancer include selective estrogen receptor modulators (SERMs) and degraders (SERDs). However, resistance to next-generation ERα antagonists remains a significant hurdle. The study suggests that this lineage switch could serve as a biomarker for identifying resistant cases early.

Understanding these epigenetic and transcriptional shifts may help develop new strategies. Early interventions could potentially block the emergence of resistant, stem-like cancer cells before they become untreatable. The findings provide a clearer picture of how resistance develops in advanced breast cancer. By targeting luminal lineage loss, future therapies might restore drug sensitivity in patients. This could improve outcomes for those who no longer respond to existing ERα-targeting treatments.